GLOBAL BIOTECH INVESTING : NEORX ( WKN 875717 ) KAUFEN!!!!!!!!!! - 500 Beiträge pro Seite

[MrGruendlich]

Global Biotech Investing empfiehlt NEORX (875717) zum Kauf!!!!


MfG MrGruendlich

[der moneymaker]

Stell doch mal ein paar Hintergrundinfos hier rein.

Ich kaufe keine Aktie ohne Infos.

[5770]

Info´s findest Du im Consorsboard unter Bio von heute ca.12Uhr
(der Bericht vom Global Biotech ...)

[toothstone]

Schaut wieder ganz gut aus. Nach Global Biotech sind wir jetzt an der
auf jeden Fall Kaufgrenze. Jeden Tag ein paar Prozent gefällt mir eh besser.

[Sugar1]

Startschuss zur Rallye?

[Sugar1]

Die Rallye hat begonnen!!!!
niemand interessierts!

[zyrtec@net]

hallo,

ich versthehe gar nicht, wie ihr auf die Empfehlungen vom GBI vertrauen könnt. Habe mir den GBI auch durchgelesen, aber es fehlt die Seriösität, scheint mir eher ein Pusherblatt zu sein.
Ich persönliche hoffe, dass die Rally später anfangen wird.

Wünsch euch was

[erkilein]

nichtsdestotrotz kam gestern abend eine Aufstufung auf buy

[erkilein]

im moment zum discountpreis in frkt zu 4,70 bei us$ 4,15

[puhvogel]

@erkilein:
Ich habe mal auf deren Homepage nachgeschaut:
Inhaltlich wirkt das auf den ersten Blick wirklich ziemlich unaufregend. Ich kenne so furchtbar viele Studien, die die Bekämpfung der Blutkrebsunterarten zum Ziele haben, dass ich eine wenig am wirtschaftlichen Erfolg von NERX zweifle, die sich gerade auf diese Thematik konzentrieren. Schau die mal die die Studiendaten von Glivec/Gleevec zB an. Das ist wirklich eine Art Wundermittel.
Der Mc Carmant hat schon recht: Die wirken wie ein klassicher Übernahmekandidat. Eine VRTX zB dagegen wird niemals übernommen werden, weil sie es einfach nicht wollen.

[erkilein]

was oder wer ist glivec und mc carmant?

[erkilein]

okay, die buy out list hab ich gefunden, aber glivec?
übrigens scheint bewegung in nerx zu kommen von instit. seite--schließen bei 3,30 und die nächsten tage rumort es...

[erkilein]

trifft hier wie bei onxx zu, deshalb nochmal:

BusinessWeek Online
INSIDE WALL STREET ONLINE -- Betting on More Biotech Buyouts


INSIDE WALL STREET ONLINE

By Gene Marcial

A significant number of mergers and acquisitions have hit the biotech sector this year. And the betting among industry pros is that more are coming. ``The recent acquisition of Aurora by Vertex, and Celera`s (NYSE:CRA - news) purchase of Axys Pharmaceuticals (AXHP) in mid-June foreshadow a new wave of consolidation in the industry,`` says John McCamanat, editor of the Medical Technology Stock Letter in Berkeley, Calif.
ADVERTISEMENT



The merger wave is partly due to a situation where many companies with exciting technology lack a sound business plan, he says. And biotech executives with solid business acumen who can steer their companies to profitability are in short supply, McCamanat believes. In addition, he says, the cash hordes built up by the larger biotechs will allow several of them to compete with the big pharmaceutical companies for prime acquisitions.

Which are the likely targets? McCamant thinks the activity will revolve around the small and midsize biotechs with market caps below $500 million. Companies that are low on cash are the most vulnerable and will usually consider a merger or acquisition to give them some measure of control over their future. One other factor that will be a key is the syngery in programs and technologies of the two companies planning to combine.

THE ``A`` LIST. Among the stocks that McCamant thinks are vulnerable to being acquired: Hyseq (HYSQ ), which seeks to discover therapeutic targets for its partners using genomics technologies and currently trades at 11.30 a share; Maxim Pharmaceuticals (MAXM ), which develops drugs for cancer and infectious diseases, now at 6.45; NeoRx (NERX ), which develops novel biopharmaceuticals for various cancers, trading at 3.50 a share; Onyx Pharmaceuticals (ONXX ), which makes drugs based on the genetics of human disease, particularly cancer, now at 11.48; Ribozyme (RZYM ), which seeks to identify gene functions, trading at 9.80; StemCells (STEM ), a developer of stem-cell-based drugs to treat diseases of the central nervous system, at 5.39; and Valentis (VLTS ), which produces proprietary gene-delivery systems, trading at 5.92.

Equally good bets for investors, says McCamant, are the large biotechs that are likely to pull the trigger in their acquisition plans. On top of McCamant`s list of would-be acquirers: Chiron (CHIR ), a major biotech focusing on producing biopharmaceuticals, vaccines, and blood-testing products, currently trading at 51; COR Therapeutics (CORR ), which specializes in cardiovascular disorders, currently at 29; Elan (ELN ), a worldwide leader in drug-delivery technology, now at 60; and Cell Genesys (CEGE ), whose gene-modification technology seeks to treat major life-threatening diseases, including prostate cancer, trading at 20.

Chiron tops McCamant`s list for these reasons: Even after acquiring Pathogenesis last year, Chiron is still on the prowl, says McCamant, because it has a need for products in the late stages of clinical trials. And Chiron has funds available that it raised recently specifically for acquisitions.

BETTER FITS. COR also needs new products, and it, too, has sufficient cash, helped by its stock, to make an acquisition. Ditto for Cell Genesys, which also has a good cash position to do a purchase to augment its own drug pipeline. And Elan has a strong history of acquisitions and is known for its ability to make quick and creative decisions. So it could, says McCamanat, announce an acquisition anytime soon.

McCamant says while the big pharmaceutical companies have larger budgets for acquisitions and are very keen on seeking biotech buyouts, he expects many of the deals will be done between the biotech companies, partly because their cultures are more compatible and also because such deals can be more synergistic than they are with the big drugmakers.

The bottom line: McCamant thinks many biotechs are currently undervalued -- and are ripe pickings for a buyout by either the major pharmceuticals or the large biotechs.


Go to www.businessweek.com to see all of our latest stories.

[puhvogel]

Bei einer Übernahme in den USA werden die Aktionäre oft über den Tisch gezogen. Da kaufen sich reichlich überbewertete Firmen billig in Technologie mit Papiergeld (eigene Aktien) ein, und die Fondmanager sind froh wenn sie 10 % Plus machen.
Gleevec ist das neue Wundermittel von Novartis für CML, das im Mai im Rekordtempo zugelassen wurde. Die news vom WO-Team von heute handeln auch von Gleevec.

[erkilein]

und sie läuft gegen den trend, deutlich im plus, scheint so als würde sie heute oder montag aus dem abwärtstrend ausbrechen

[erkilein]

vergleicht man die Thalomidergebnisse (CELG) mit denen von STR (NERX), dann ist celgene meilenweit von einem erfolg weg, möglicherweise schluckt celg sogar nerx, weil deren phase III im moment blockiert ist

hier ein ausschnitt eines boardmitglieds bzgl des vergleiches, ich kann nichts falsches entdecken--sollte die fda str wieder zulassen--sind 50-100 % für nerx nicht unwahrscheinlich.

thalomid vrs. str
by: ahoymite (49/M/`octopuses garden`)
Long-Term Sentiment: Strong Buy 07/09/01 10:53 pm
Msg: 29002 of 29016

..from myeloma.org...

"DEFINITION OF CLINICAL RESPONSE
To determine the clinical response to therapy there are several schemes. The following one is used frequently:



CR (complete response) Standard definition: (1)
75% reduction in serum myeloma protein level (>90% in urine). This has been a long standing definition used by SWOG.
(2)True complete remission More stringent definition requiring: elimination of M-component from serum and urine plus no evidence of myeloma in the bone marrow
PR (partial response)* >50% <75% regression
OR (objective response or >25% <50% regression stable disease)*
NR (no response) <25% regression or progressive disease
*Many variations of this are in use. The improvements in M-component must also be associated with other evidence of clinical improvement (reduced bone pain, improved anemia, etc.). It has become clear from recent analyses that with the possible exception of "true complete remission" (CR definition 2) it is important to keep in mind that the exact percentage regression (i.e. % reduction in myeloma protein level) does not greatly influence the response duration or survival. When there is residual disease, the characteristics of the remaining myeloma cells (drug resistant) determine the outcome. The fraction of resistant myeloma cells is primarily dependent upon the initial (pretreatment) tumor burden or stage.

Typically, responding patients go from a high risk status, to a lower risk status until, eventually, in the ideal situation, no signs of the multiple myeloma are left. Responding patients typically achieve a stable plateau phase with clearly measurable residual disease. The time required to achieve the plateau phase is quite variable ranging from 3-6 months (rapid response) to 12 - 18 months (slow response)."
http://www.myeloma.org/TheIMF/imf_mmc.html

NeoRx STR produces 50-60% CR...

from todays thalomid results.."Of the study`s 169 patients, 37 percent demonstrated a greater than or equal to 25 percent reduction in myeloma protein, 30 percent demonstrated a greater than or equal to 50 percent reduction and 14 percent of patients achieved a complete or near complete response."

..that`s 14% CR for thalomid vrs. 55% CR
for STR...which do you think will become `First
Line` treatment...duh

[DoktorKulka]

laut Global Bio soll Neorx in 1 jahr 2oo % machen

2 USD /Aktie

ds Investmenthaus Raymond hat ein KZ von 8 USD also ca 1o Euro
STR Programm soll wieder von der FDA getestet werden

[puhvogel]

@Erkilein: Was soll mit dem Management sein?

[erkilein]

aktionärsunfreundlich in PR-sachen, zu viele wissenschaftler im management statt "verkäufer". kurspflege sag ich da, neues 52-wochen-Low heute...schrott und ab morgen geht der ganze biotechsektor nochmal 10-20 % runter, weil die nasdaq alles wieder abgibt und bio heute schwach war--long lohnt sich noch nicht

[erkilein]

dennoch, aufgepasst


könnt was werden, wenn se 3,90 knacken.

[erkilein]

sorry 3,50 reicht zum break

[erkilein]

ready to go

[erkilein]

break geschafft!

[erkilein]

damit wurde der 6 monatige AbwTrend gebrochen!
stoch,rsi und momentum haben bullische divergenzen, kann es sein, dass die FDA demnächst STR doch noch für Phase III zuläßt? Das könnte mit dem chart in ein paar wochen dann hinkommen. Wenn dies passiert, schließt NERX das Gap bei 17 $. Das wären 400 %. Eine Spekulation könnte dies wert sein, zumal NERX im moment mit etwas mehr als der cashpos. bezahlt wird und ein weiteres medikament sich in Phase III befindet.

[DerBernecker]

Guten Tag!

@..und wenn diese Selbsternannten Gurus empfehlen von der Brücke zu springen?Sie springen...

Guten Tag
DerBernecker

[DoktorKulka]

bernecker

Sehr schlau herr bernecker weiter so, auf diese Kommentare, die so informativ sind, warten wir immer.

PS ist das der gleiche Bernekcer, der mit seiner Briefpost mir den Briefkasten vollmüllt????????????

drk

[erkilein]

scheinbar...,
wahrscheinlich traut er sich auch nicht von seiner eigenen Brücke in Bad Berneck zu springen

[DoktorKulka]

Herrn Berecker

dann würde ich mal wieder ins NTV gehen und dann können Sie wieder Ihre Depressionen und klugscheißerei loswerden

auf diese Art von Leuten, die ihren negativen Scheiß loswerden wollen, kann ich gern verzichten.

Schreib weiter Deine Infobriefe und verpulver sinnlos Porto, aber lass uns hier in Ruhe

Mit unfreundlichen Grüßen Dr. K und gute Nacht

[erkilein]

bernecker, hätteste mal lieber besser recherchiert

[DoktorKulka]

aktuell bei 4 USD

mal sehen, ob noch was drin ist

Dr.K

[johnnywinter]

.....Hier die Zahlen...

Gruß

Johnnywinter



Business Editors/Health & Medical Writers
SEATTLE--(BW HealthWire)--July 20, 2001--NeoRx Corporation (Nasdaq:NERX) today reported a net loss of $5.6 million ($0.22 diluted per share loss after preferred dividends) for the second quarter of 2001, compared to a net loss of $3.9 million ($0.17 diluted per share loss after preferred dividends) for the second quarter ended June 30, 2000.
Revenue for the second quarter 2001 was $37 thousand compared to $0.7 million in the second quarter of 2000. Revenue for the second quarter of 2001 was primarily from government grants. Revenue for the second quarter of 2000 consisted primarily of a $0.5 million milestone payment from Angiotech Pharmaceuticals, Inc. („Angiotech“), government grants and licensing revenue from Theseus, Ltd., under an agreement licensing certain technology unrelated to NeoRx‘s primary product development programs.
Other income for the second quarter of 2001 was $0.8 million compared to $0.5 million for the second quarter of 2000, which consisted primarily of interest income from short-term investments and rental income. Other income for the first six months of 2001 included $3.3 million of realized gains on the sale of the Company‘s shares of Angiotech.
Total operating expenses for the second quarter of 2001 increased 27% to $6.4 million from $5.1 million in 2000. Research and development expenses increased 8% from $8.1 million to $8.7 million for the six months ended June 30, 2001. The increase in research and development costs for the second quarter of 2001 is primarily the result of increased operating costs for our new radiopharmacy facility in Denton, Texas, acquired on April 19, 2001. Second quarter research and development costs also increased as the result of higher costs for supplies related to our PRETARGET® technology.
General and administrative expenses increased 8% to $1.7 million for the second quarter of 2001 from $1.6 million for the same time period in 2000 and increased 5% from $3.1 million to $3.3 million for the six months ended June 30, 2001. The increases in general and administrative costs during the second quarter and first half of 2001 are primarily due to non-cash expenses for outside consulting services.
Cash and investment securities as of June 30, 2001 were $43.1 million compared to $57.6 million at December 31, 2000. Approximately $7.3 million of cash used during the second quarter of 2001 was for the acquisition of the radiopharmacy facility located in Denton, Texas. The balance of the cash used during the second quarter was spent to fund NeoRx Corporation‘s operating costs.
Seattle-based, NeoRx Corporation is developing innovative products designed to provide improved treatments for patients with cancer.
This release contains forward-looking statements relating to the development of the Company‘s products and future operating results that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words „believe,“ „expect,“ „intend,“ „anticipate,“ variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company‘s actual results include the progress and costs of clinical trials and the timing of regulatory approvals. Reference is made to the Company‘s latest Annual Report on Form 10 - K filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.
Visit NeoRx at www.neorx.com.
To receive NeoRx news releases via email, register at
www.neorx.com/news/pr.html.
NeoRx and PRETARGET are registered trademarks of NeoRx Corporation in the United States and/or foreign countries.
©2001 NeoRx Corporation. All Rights Reserved.
 0-
*T
NeoRx Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2001 2000 2001 2000
------------------ -----------------


REVENUES $37 $727 $1,076 $904
-------- -------- -------- --------
OPERATING EXPENSES:
Research and development 4,751 3,496 8,671 8,050
General and administrative 1,693 1,566 3,259 3,103
-------- -------- -------- --------
Total operating expenses 6,444 5,062 11,930 11,153
-------- -------- -------- --------

Loss from operations (6,407) (4,335) (10,854) (10,249)
Other income, net 837 480 1,703 4,028
-------- -------- -------- --------
Net loss $(5,570) $(3,855) $(9,151) $(6,221)
======== ======== ======== =======

Preferred stock dividends (125) (127) (250) (254)
-------- -------- -------- --------
Net loss applicable
to common shares $(5,695) $(3,982) $(9,401) $(6,475)
======== ======== ======== =======
Loss per share:
Basic and diluted $(0.22) $(0.17) $(0.36) $(0.29)
======== ======== ======== =======
Shares used in calculation
of loss per share:
Basic and diluted 26,394 23,287 26,320 22,325
======== ======== ======== ========


Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
June 30, 2001 Dec. 31, 2000
------------- -------------
ASSETS:
Cash and investment securities $43,123 $57,578
Facilities and equipment, net 15,516 1,644
Other assets 4,949 5,236
-------- --------
Total assets $63,588 $64,458
======== =======

LIABILITIES AND SHAREHOLDERS‘ EQUITY:
Current liabilities $1,999 $2,213
Long-term liabilities 6,075 --
Shareholders‘ equity 55,514 62,245
-------- --------
Total liabilities and
shareholders‘ equity $63,588 $64,458
======== =======
*T
 30--AMP/se*

CONTACT: NeoRx Corporation
Stacie D. Byars, 206/286-2508
KEYWORD: WASHINGTON
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL EARNINGS For the best viewing of the news releases please use the following email settings: Courier 10 point.
 Notice of Copyright and General Disclaimer-
© 2000 Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire‘s members who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user‘s reference, is prohibited without prior written permission.

[DoktorKulka]

also da ich schlecht englisch lesen kann, gutes Ergebnis oder?

vielleicht kann mal einer die Zahlen kommentieren

Danke

gruss drk

[erkilein]

keine sonderlich guten ergebnisse, aber genug cash für pretarget, etwas höhere Ausgaben wegen dem fabrikkauf von isotopes--falls str noch grünes licht bekommt, stehen dafür vorerst 6 mio privat parat--außerhalb des zahlenwerkes--cash insgesamt noch 46 mio, aber deutlich ausreichend--der markt hatte wohl schlechteres erwartet...

[DoktorKulka]

danke

in USA ja noch 7 % Plus . bio global inv soll ja str wieder kommen, mal sehen, was die zeit bringt

k

[erkilein]

kaufen!--wir sind bald wieder bei 4 $, drüber wirds heftig

[johnnywinter]

News:

Gruß

Johnny

Business Editors/Health and Medical Writers
SEATTLE--(BW Healthwire)--July 31, 2001--
 Board Accepts Resignation of Paul G. Abrams;
Douglass B. Given Named as New Chief Executive—
NeoRx Corporation (Nasdaq:NERX) today announced the resignation of Paul G. Abrams, MD, JD, as its President and Chief Executive Officer and as a Director of the Company and, effective immediately, the appointment of Douglass B. Given, MD, PhD, to these positions. Dr. Given served as a consultant to the Company since November 2000. Previously, he was Senior Vice President and Chief Technology Officer at Mallinckrodt, Inc. On June 5, 2001, NeoRx announced the appointment of Wolfgang Oster, MD, as its new Chief Operating Officer. Dr. Oster will continue in that position.
Dr. Given brings substantial managerial, operational and regulatory experience to NeoRx, through his nearly twenty years in the pharmaceutical and biotechnology industries. Prior to his position at Mallinckrodt, he was President and CEO of Progenitor, Inc., and held executive positions with Schering-Plough Corporation and GD Searle/Monsanto Company. In these positions, he directed research, medical affairs, regulatory, manufacturing and commercial operations.
„This appointment comes at a pivotal time for NeoRx, as we move our products in development through regulatory review to commercialization; Doug has the experience to lead the company to the next level,“ said Fred. B. Craves, PhD, Chairman of the Board of Directors. „We are grateful to Paul Abrams for his seventeen years with the company, building our science base and pipeline of potential products, and placing NeoRx at the forefront of innovative therapies for myelomas, lymphomas and other cancers.“
Dr. Abrams, who joined NeoRx in 1984 as Vice President and Medical Director and was appointed CEO in May 1990 and President in March 2001, has agreed to provide consulting services to the Company.
„With the recent additions of Dr. Wolfgang Oster as Chief Operating Officer, and Dr. Richard Ghalie as Vice President of Medical and Regulatory Affairs, both with strong oncology drug development experience, and now with Dr. Given, who has a solid industry background, I believe I leave the company in excellent hands,“ said Dr. Abrams.
Seattle-based, NeoRx Corporation is developing innovative products designed to provide improved treatments for patients with cancer.
This release contains forward-looking statements relating to the development of the Company‘s products and future operating results that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words „believe,“ „expect,“ „intend,“ „anticipate,“ variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company‘s actual results include the progress and costs of clinical trials and the timing of regulatory approvals. Reference is made to the Company‘s latest Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.
Visit NeoRx at www.neorx.com. To receive NeoRx news releases via email, register at www.neorx.com/news/pr.html.
NeoRx is a registered trademark of NeoRx Corporation in the United Stated and/or foreign countries.
© 2001 NeoRx Corporation. All Rights Reserved.
 30--kmw/se*

CONTACT: NeoRx Corporation
Douglass B. Given, M.D.
President and Chief Executive Officer
206/281-7001 x 528
or
Wolfgang Oster, M.D.
Chief Operating Officer
206/281-7001 x 538

KEYWORD: WASHINGTON
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL MEDICAL
MANAGEMENT CHANGES
For the best viewing of the news releases please use the following email settings: Courier 10 point.
 Notice of Copyright and General Disclaimer-
© 2000 Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire‘s members who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user‘s reference, is prohibited without prior written permission.

[DoktorKulka]

was soll das?????

der kurs fällt ja

[DoktorKulka]

5 % plus ist wenig aber besser als nichts

also langsam gehts aufwärts bei dem sog. Crash


alles verkaufen damit die Ganoven billig einkaufen können